CoChat

American Heart Association Atrial Fibrillation Research Summit: A Conference Report From the American Heart Association

Open access
Estes, N.A. Mark, Sacco, Ralph L., Al-Khatib, Sana M., Ellinor, Patrick T., Bezanson, Judy, Alonso, Alvaro, Antzelevitch, Charles, Brockman, Randall G., Chen, Peng-Sheng, Chugh, Sumeet S., Curtis, Anne B., DiMarco, John P., Ellenbogen, Kenneth A., Epstein, Andrew E., Ezekowitz, Michael D., Fayad, Pierre, Gage, Brian F., Go, Alan S., Hlatky, Mark A., Hylek, Elaine M., Jerosch-Herold, Michael, Konstam, Marvin A., Lee, Richard, Packer, Douglas L., Po, Sunny S., Prystowsky, Eric N., Redline, Susan, Rosenberg, Yves, Van Wagoner, David R., Wood, Kathryn A., Yue, Lixia, Benjamin, Emelia J. · 2011 · Circulation
Cited by 35

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

A trial fibrillation (AF) poses a major global public health challenge because it is increasing in prevalence and is associated with an increased risk of stroke, dementia, heart failure, and death.[1][2][3] In response to the many challenges posed by AF, the American Heart Association (AHA) convened a conference in Washington, DC, on June 12-13, 2010, that included patients, nurses, physicians, and healthcare policy makers and regulators.In addition, basic, translational, population, outcomes, and clinical scientists participated (Appendix).The 22 presentations and 6 panel discussions were organized into 4 sessions: (1) Mechanisms of AF: Basic and Translational Science and Genetics; (2) Epidemiology, Outcomes, Cost, AF, and Stroke Prevention; (3) Meeting the Clinical Challenges in AF; and (4) Redefining the Therapeutic Goals of AF (Appendix).The focus of the present report is to provide an overview of the key concepts presented and the core recommendations made by the summit participants. Mechanisms of AF: Basic and Translational Science and GeneticsAttempts to develop safe and effective pharmacological therapy for AF have focused on atrium-selective drugs that take advan-tage of electrophysiological differences between the atrium and ventricle.4 -7 Heterogeneous abbreviation of the effective refractory period within the atrium provides the electric substrate for development of AF.The reduced effective refractory period results from abbreviation of the atrial action potential duration, which is caused by a decrease in the calcium channel current (I Ca ) and an increase in the potassium channel current (I K1 ) and the constitutively active acetylcholine-sensitive current (CA I KACh ). 4 -7 Maintenance of AF is facilitated by structural remodeling and additional abbreviation of the effective refractory period.The principal goal of pharmacological therapy is therefore to augment the effective refractory period.Distinctions in the ion channel currents between the atrium and ventricle open the possibility for development of atriumspecific and -selective drugs for rhythm control of AF, which might avoid ventricular proarrhythmic effects.Atriumspecific targets include I Kur , I KACh , and the constitutively active I KACh , the most investigated of which is inhibition of I Kur .7 Recent experimental studies have identified atriumselective I Na blockers that can effectively suppress AF while exerting little or no effect in the ventricles.5,6 Combinations of The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel.Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This document was approved by the American Heart Association Science Advisory and Coordinating Committee on May 9, 2011.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/cir.0b013e318224b037

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 35

Metadata

Authors
Estes, N. A. M., Sacco, R. L., Al-Khatib, S. M., Ellinor, P. T., Bezanson, J., Alonso, A., Antzelevitch, C., Brockman, R. G., Chen, P.-S., Chugh, S. S., Curtis, A. B., DiMarco, J. P., Ellenbogen, K. A., Epstein, A. E., Ezekowitz, M. D., Fayad, P., Gage, B. F., Go, A. S., Hlatky, M. A., Hylek, E. M., Jerosch-Herold, M., Konstam, M. A., Lee, R., Packer, D. L., Po, S. S., Prystowsky, E. N., Redline, S., Rosenberg, Y., Van Wagoner, D. R., Wood, K. A., Yue, L., & Benjamin, E. J.
Venue
Circulation
Published
2011-07-19
Volume
124
Issue
3
Pages
363-372
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2034714284
Cited by
35
References
14
FWCI
3.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: American Heart Association Atrial Fibrillation Research Summit: A Conference Report From the American Heart Association. https://app.cochat.ai/papers/10.1161/cir.0b013e318224b037
The paper
Estes, N. A. M., Sacco, R. L., Al-Khatib, S. M., Ellinor, P. T., Bezanson, J., Alonso, A., Antzelevitch, C., Brockman, R. G., Chen, P.-S., Chugh, S. S., Curtis, A. B., DiMarco, J. P., Ellenbogen, K. A., Epstein, A. E., Ezekowitz, M. D., Fayad, P., Gage, B. F., Go, A. S., Hlatky, M. A., . . . Benjamin, E. J. (2011). American Heart Association Atrial Fibrillation Research Summit: A Conference Report From the American Heart Association. Circulation. https://doi.org/10.1161/cir.0b013e318224b037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.